Related Experiment Video
Updated: May 15, 2025
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
Outcomes of Treatment in Ocular Myasthenia Gravis Based on Minimal Manifestation: A Real-World Retrospective Cohort
Parinee Kemchoknatee1, Boonravee Santitamrongvtit2, Thansit Srisombut3
1Department of Ophthalmology, Rajavithi Hospital, Rangsit University, Bangkok, Thailand.
Background:
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness caused by autoantibodies targeting acetylcholine receptors. Prednisolones improve symptoms by reducing autoantibody activity, but its optimal use, particularly in ocular myasthenia gravis (OMG), remains unclear due to limited trials and variable responses.
Objective:
To evaluate the clinical efficacy, optimal dosing, and predictors of first minimal manifestation (MM) with oral prednisolone in myasthenia gravis, based on the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS).
Methods:
Patients with OMG treated with oral prednisolones between 1st January 2015 and 31st December 2022 at Rajavithi Hospital were retrospectively reviewed. Baseline data, dosing, efficacy, and outcomes were analyzed using Cox regression and survival curves to identify predictors and time to first MM.
Results:
Of the 101 OMG, 81 patients (80.2%) achieved MM. The mean age was 46.6 ±6.9 years in the MM group and 46.2 ± 6.0 years in the non-MM group. The mean daily dose of pyridostigmine was significant higher in the MM group (152.68 ± 32.38 mg/day) compared to the non-MM group (133 ± 34.50 mg/day) (p = 0.018). The prednisolone dosage was comparable between the two groups. Seropositivity of AChRAb, thymoma, thymectomy, concurrent autoimmune diseases were notably observed in non-MM group (p < 0.05, respectively). Cox proportional hazards analysis and survival curves revealed higher pyridostigmine dosage (HR 1.713, 95% CI: 1.029-2.849, p = 0.038). Prednisolone initiation at 6-12 months reduced MM (HR 0.527, 95% CI: 0.297-0.936, p = 0.029), with further reduction observed beyond 12 months (HR 0.165, 95% CI: 0.073-0.368, p < 0.001). The presence of AChRAb, thymoma, prednisolones dosage and ophthalmic manifestations demonstrated no significant association with the achievement of minimal manifestation.
Conclusion:
Early prednisolone initiation (within 6 months) and higher pyridostigmine doses were linked to remission, highlighting treatment factors over demographics in OMG outcomes.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...